Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Swallowing Exercises Crucial After RT in Head and Neck Cancer

May 4th 2017

Lynn Acton, MS, CCC (SLP), discusses the significance of swallowing modalities for patients with head and neck cancer.

Rationale for Targeting Galectin-1 in Head and Neck Cancer

May 4th 2017

Dhanya K. Nambiar, PhD, Stanford University, explains the rationale behind targeting Galectin-1 (Gal-1) in head and neck cancer.

Expert Sheds Light on Investigative Surgical Approaches in Head and Neck Cancer

May 3rd 2017

Benjamin L. Judson, MD, highlights the importance of a multidisciplinary team and shares insight on some of the advancements related to surgery for patients with head and neck cancer.

Dr. Burtness on Evolution of Molecular Testing in Head and Neck Cancer

May 3rd 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the evolution of molecular testing in head and neck cancer.

Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

May 1st 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck Radiation

May 1st 2017

A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.

Dr. Papa on the Impact of CAR T Cell Trial in Head and Neck Cancer

April 27th 2017

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.

Combinations with Radiation for Head and Neck Cancer

April 27th 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses combinations with radiation therapy for patients with head and neck cancer.

Expert Discusses Immunotherapy Advances in Head and Neck Cancer

April 25th 2017

Barbara Burtness, MD, discusses her presentation on the current and emerging role of immunotherapy for patients with head and neck cancer.

Dr. Seiwert on Managing Side Effects for Head and Neck Cancer Treatment

April 25th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

Dr. Nambiar on Next Steps with Galectin-1 for Head and Neck Cancer

April 21st 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses the next steps with targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in patients with head and neck cancer.

Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck Cancer

April 21st 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

CAR T-Cell Therapy Shows Potential in Head and Neck Cancer

April 19th 2017

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

Researchers Identify Predictors for Distant Metastases in HPV+ Oropharyngeal Cancer

April 13th 2017

Shlomo Koyfman, MD, discusses the findings of a recent study of patients with HPV-positive oropharyngeal cancer treated with cisplatin-based chemoradiotherapy or cetuximab-based bioradiotherapy.

Galectin-1 Inhibition Shows Early Promise in Head and Neck Cancer

April 12th 2017

Dhanya Nambiar, PhD, discusses the role of galectin-1 in the tumor microenvironment, and the potential for targeting this protein in patients with head and neck cancer.

Exploring Residual Concentrations of Agents in Head and Neck Cancer

April 10th 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Pembrolizumab Impresses in Heavily Pretreated Head and Neck Cancer

April 7th 2017

Pembrolizumab has shown durable, clinically significant responses in patients with locally advanced head and neck cancer who are refractory to platinum-based chemotherapy and cetuximab, according to results from the single-arm, phase II KEYNOTE-055 study.

Targeting Galectin-1 With Radiation and Immune Checkpoints in Head and Neck Cancer

April 7th 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in head and neck cancer.

Dr. Papa on CAR T-Cell Therapy for Head and Neck Cancer

April 6th 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Dr. Ciccolini on Residual Concentrations of Cetuximab in Head and Neck Cancer

April 6th 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses residual concentrations of cetuximab (Erbitux) in patients with head and neck cancer.